AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback